We have shown that KMT2D-activated tumor-suppressive super-enhancers interact with the promoters of the DNA methyltransferase gene Dnmt3a and the medulloblastoma suppressor gene Bcl6 and upregulate these genes to suppress medulloblastoma genesis [31]. This evidence concerns the gene KMT2D and neoplasm.